Navigation Links
Galmed Pharmaceuticals Reports First Half 2014 Financial Results
Date:7/25/2014

thereby permitting Galmed to conduct clinical studies for the targeted indication and additional proof of concept studies in the United States in the future.
  • Filed a Fast Track Designation request with the FDA.
  • Published the results of Galmed's Phase IIa trial of aramchol in the peer-reviewed Clinical Gastroenterology and Hepatology Journal.
  • Commenced on schedule, pharmacokinetic and food effect studies in 66 subjects for the higher doses of aramchol that the Company anticipates using in its Phase IIb trial of aramchol for the treatment of Non-Alcoholic Steato-Hepatitis, or NASH, patients who are also overweight and diabetic.
  • Filed a provisional patent application in the United States for aramchol to treat lipodystrophy, a medical condition characterized by abnormal or degenerative conditions of adipose tissue, or body fat, including the loss of body fat from various regions of the body and its redistribution and accumulation in other areas and for which there is no currently approved medical treatment, based on Galmed's Phase IIa clinical trial of aramchol in 60 non-alcoholic fatty liver disease, or NAFLD, patients, in which a significant reduction in liver fat and improvement of certain metabolic parameters were observed.
  • Independent publication of the importance of the regulation of ABCA1-induced reverse cholesterol transport on the pathogenesis of NASH, which may further support Galmed's belief that aramchol can play a significant role in the pathogenesis of NASH based on Galmed's studies showing the affect of aramchol in increasing ABCA1 activity in in vitro models of human cells by between 300% and 400%.
  • "I am pleased to report that we have completed all short-term milestones that we set for the first half of 2014 at the time of our initial public offering," stated Allen Baharaff, Galmed's Chief Executive Officer. "We are also moving ahead with trial p
    '/>"/>

    SOURCE Galmed Pharmaceuticals Ltd.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
    2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
    3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
    4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
    5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
    6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
    7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
    8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
    9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
    10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
    11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
    (Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
    (Date:12/19/2014)... December 19, 2014 BioPlus Specialty ... pharmacies, announces the promotion of Nick Maroulis, Pharm.D. to ... Pharmacy Services. , In this position, Dr. Maroulis ... also managing the directors of our multi-site pharmacies as ... since 1997 and during that time he has served ...
    (Date:12/19/2014)... -- Bina Technologies, Inc. (Bina, Redwood City, ... been acquired by Roche (SIX: RO, ROG; OTCQX: RHHBY).  ... that provides a big data platform for centralized management ... the academic and translational research markets.  Bina will be ... to focus on development of their innovative genomic analysis ...
    Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
    ... The Netherlands and BARCELONA, Spain, July 15, Agendia ... will give Ferrer exclusive rights to sell two ... prognostic test,that uses a 70-gene signature to indicate ... gene expression profiling service which offers,a fast and ...
    ... Schizophrenia is a disease that strikes an average ... psychiatric disorder are not yet clear. But now, VIB ... that a disturbed cleavage of the Nrg-1 protein lies ... Greater understanding of this molecular process is a first ...
    ... to Host Conference Call to Update Clinical Program ... Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it ... clinical studies with,REOLYSIN(R), its proprietary formulation of the ... substantial momentum in the past year,culminating in the ...
    Cached Biology Technology:Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets 2Agendia and Ferrer Announce Exclusive Agreement for Sales of Cancer Diagnostic Services in Four Major European Markets 3Incorrectly cleaved protein leads to schizophrenia 2Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 2Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R) 3
    (Date:12/17/2014)... Va. , Dec. 15, 2014 ... to make it easier to detect and prevent ... Today the agency started performing an ... capability will validate the authenticity of purchased microcircuits ... The new quality control measures will be conducted ...
    (Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
    (Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays ... a while. Hypertension – the medical term for high blood ... early 1800s, and the inflatable cuff that,s used in measuring ... however, mean there,s nothing new about hypertension, its triggers and ... beliefs about the condition and the best ways to treat ...
    Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
    ... The world,s top scientists and clinicians in the ... present their latest research findings at the 60th Annual ... Tuesday, November 2, through Saturday, November 6, 2010, at ... Founded in 1948, the American Society of Human Genetics ...
    ... 2010 The American Society of Agronomy (ASA), Crop ... of America (SSSA) will present the following 2010 Scholarships ... 3 in Long Beach, CA, www.acsmeetings.org . ... The Hank Beachell Future Leader Scholarship, funded through ...
    ... stem (hPS) cells can generate any given cell type ... are of interest to stem cell scientists working on ... heart disease, diabetes, arthritis, and other ailments. Before ... however, some obstacles must first be overcome. One ...
    Cached Biology News:American Society of Human Genetics to host 60th Annual Meeting in Washington, D.C. 2American Society of Human Genetics to host 60th Annual Meeting in Washington, D.C. 3ASA, CSSA and SSSA present scholarships and fellowships 2ASA, CSSA and SSSA present scholarships and fellowships 3ASA, CSSA and SSSA present scholarships and fellowships 4ASA, CSSA and SSSA present scholarships and fellowships 5ASA, CSSA and SSSA present scholarships and fellowships 6ASA, CSSA and SSSA present scholarships and fellowships 7ASA, CSSA and SSSA present scholarships and fellowships 8ASA, CSSA and SSSA present scholarships and fellowships 9Researchers at UC Riverside find solution to cell death problem vexing stem cell research 2
    ... Afinity Purified Tyrosine Hydroxylase (Ser40) ... was raised against synthetic phosphopeptide ... surrounding the phospho-Ser40 of rat ... was purified by sequential chromatography ...
    NF kappa B Related Sampler Kit 10g each...
    ... Kits synthesize RNA probes with specific activities ... High specific activity, single-stranded RNA probes are ... hybridization, and blot hybridizations. MAXIscript Kits can ... modest amounts of unlabeled RNA (2-4 g/20ul ...
    ... SeeDNA co-precipitant, 250 ... pink color ensures easy ... nucleic acid recovery.Chemically inert, ... biology applications.Simple 5-minute protocol. ...
    Biology Products: